tiprankstipranks
Advertisement
Advertisement
Simulations Plus: Solid Q2 and Long-Term Potential Tempered by EPS Headwinds and Biopharma Spending Uncertainty Supporting Hold Rating
PremiumRatingsSimulations Plus: Solid Q2 and Long-Term Potential Tempered by EPS Headwinds and Biopharma Spending Uncertainty Supporting Hold Rating
25d ago
Closing Bell Movers: Markets on edge ahead of US-Iran talks
Premium
The Fly
Closing Bell Movers: Markets on edge ahead of US-Iran talks
25d ago
Simulations Plus Reports Q2 2026 Results, Trims EPS Outlook
Premium
Company Announcements
Simulations Plus Reports Q2 2026 Results, Trims EPS Outlook
25d ago
Simulations Plus announces collaboration programs for AI-enabled modeling
PremiumThe FlySimulations Plus announces collaboration programs for AI-enabled modeling
1M ago
Simulations Plus Shareholders Approve Directors and Equity Plan
Premium
Company Announcements
Simulations Plus Shareholders Approve Directors and Equity Plan
2M ago
Simulations Plus announces extensions of FDA and NIEHS research collaborations
Premium
The Fly
Simulations Plus announces extensions of FDA and NIEHS research collaborations
3M ago
Simulations Plus reports Q1 adjusted EPS 13c, consensus 20c
PremiumThe FlySimulations Plus reports Q1 adjusted EPS 13c, consensus 20c
4M ago
Simulations Plus backs FY26 adjusted EPS view $1.03-$1.10, consensus $1.03
Premium
The Fly
Simulations Plus backs FY26 adjusted EPS view $1.03-$1.10, consensus $1.03
4M ago
Simulations Plus price target raised to $19 from $16 at TD Cowen
Premium
The Fly
Simulations Plus price target raised to $19 from $16 at TD Cowen
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100